ClinicalTrials.gg
CompletedNCT04015232Updated Oct 4, 2019Results posted

Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

A Phase 1 interventional study of INTP5 and US Neulasta in Immunogenicity and Healthy Volunteers, sponsored by Intas Pharmaceuticals, Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Intas Pharmaceuticals, Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2018, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Intas Pharmaceuticals Ltd. proposed biosimilar INTP5 compared to innovator product, US-Neulasta) in healthy, adult, human subjects under fed conditions.

02

Conditions studied

  • Immunogenicity
  • Healthy Volunteers

Keywords

  • Pegfilgrastim
  • Biosimilar
  • Immunogenicity
  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • Healthy Volunteers
03

In context

Lead sponsor

Intas Pharmaceuticals, Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
  2. Having body weight ≥50 kg and (BMI) between 18.5 and 29.9 (both inclusive), calculated as weight in kg/height in meter\^2.
  3. Not having any significant disease in medical history or abnormal findings during screening, abdominal ultrasonography, medical history, clinical examination, laboratory evaluations, 12-lead echocardiogram () and chest X-ray (posterior-anterior view; within the last 6 months) recordings.
  4. Able to understand and comply with the study procedures, in the opinion of the investigator.
  5. Able to give voluntary written for participation in the trial.
  6. In case of female subjects:

    • Surgically sterilized at least 6 months prior to study participation; Or If a woman of child bearing potential is willing to use a suitable and effective double barrier method or intra uterine device during the study.
    • Serum pregnancy test (for female subjects) must be negative.

Exclusion criteria

Exclusion criteria:

  1. Known to the study drug or its constituents and/or hypersensitivity to E. coli derived proteins, and/or previous exposure to the study drug.
  2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  3. Known case of hereditary fructose intolerance.
  4. Subjects with latex allergies will be excluded as the needle cover on the single-use prefilled syringe contains dry natural rubber (latex).
  5. Any laboratory finding including (ANC), , red blood cells (RBC) count, and level at the time of screening.
  6. Prior exposure to any peptide colony stimulating or growth factor, including erythropoietin, filgrastim or Pegfilgrastim; Prior exposure to any vaccines, immunoglobulin preparations or immunomodulators within the past 6 months prior to receiving first dose; evidence of E. coli diarrhea or diseases within 3 months.
  7. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAIDs induced urticaria.
  8. Subjects with a history of pulmonary infiltrate or pneumonia in the last 6 months.
  9. History of any hematologic disease including sickle cell disorders.
  10. Ingestion or use of any prescribed medication at any time within 1 month prior to receiving first dose.
  11. Receipt of over-the-counter medicines which have not yet cleared from the body (5 half-lives must have passed for the medicine to be considered to have cleared from the body).
  12. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or alcoholic products within 72 hours prior to receiving study medicine.
  13. Smokers, who smoke 10 or more than 10 cigarettes/day or inability to abstain from smoking during the study.
  14. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
  15. Donation of blood (1 unit or 350 mL) or equivalent amount of blood substitute.
  16. Receipt of an medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
  17. Positive result for (HIV I \&/or II) and/or and C tests.
  18. History or presence of cancer because of which anticipated life span is less than 5 years as per the investigator's assessment.
  19. History or presence of psychiatric disorders.
  20. Presence of tattoo or scars or any type of skin lesions due to infection, burning, wound or inflammation at the proposed site of injection.
  21. An unusual diet, for whatever reason (e.g. low-sodium), for 4 weeks prior to receiving the study medicine. In any such case, subject selection will be at the discretion of the Principal Investigator.
  22. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving study drug.
  23. A history of difficulty in donating blood.
  24. Females, pregnant or lactating, or planning to become pregnant during the time the subject is on study or found positive in pregnancy test at screening.
  25. Any infections in the last 4 weeks before receiving study medication.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    INTP5 biosimilar product

    INTP5 subcutaneously at a dose of 6 mg/0.6 mL.

    Combination Product: INTP5

  • Active comparator
    US Neulasta reference product

    US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.

    Combination Product: US Neulasta

Interventions

  • Combination productINTP5

    INTP5, a pegfilgrastim biosimilar to US Neulasta.

  • Combination productUS Neulasta

    US Neulasta: FDA approved pegfilgrastim innovator product.

06

What researchers measure

Primary outcomes

  1. Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.

    Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data. Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant. Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.

    Time frame: Samples (8 mL each) were withdrawn at screening, at pre-dose and at 336 (D-15, Week 2), 504 (D-22, Week 3, within 60 minutes before 2nd dose), 840 (D-36, Week 5), 1176 (D-50, Week 7), 1680 (D-71, Week 10) and 2016 (D-85, Week 12) hours after first dose.

Secondary outcomes

  1. PK Endpoints: Pegfilgrastim C[Max]

    Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration. Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  2. PK Endpoints: Pegfilgrastim AUC[0-t]

    Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  3. PK Endpoints: Pegfilgrastim AUC[0-∞]

    Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC\[0-infinity\] is the sum of measurable and extrapolated parts.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  4. PK Endpoints: Pegfilgrastim T[Max]

    The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  5. PK Endpoints: Pegfilgrastim λz (Lambda-z)

    Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  6. PK Endpoints: Pegfilgrastim R^2 Adjusted

    Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R\^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  7. PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]

    The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\[0-t\])/AUC\[0-infinity\]\] x 100.

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  8. PK Endpoints: Pegfilgrastim t[1/2]

    The terminal half-life calculated using the formula 0.693/(lambda-z)

    Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.

  9. PD Endpoints for Baseline Non-adjusted ANC: E[Max]

    Maximum measured absolute neutrophil count (ANC).

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  10. PD Endpoints for Baseline Non-adjusted ANC: T[Max]

    Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  11. PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]

    Time to reach the maximum measured absolute neutrophil count (ANC)

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  12. PD Endpoints for Baseline Adjusted ANC: E[Max]

    Maximum measured absolute neutrophil count (ANC).

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  13. PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]

    Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  14. PD Endpoints for Baseline Adjusted ANC: T[Max]

    Time to reach the maximum measured absolute neutrophil count (ANC)

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  15. PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)

    First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

  16. PD Endpoints for Baseline Adjusted ANC: t[1/2]

    The terminal half-life will be calculated as 0.693/(lambda-z)

    Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.

07

Results

Posted Oct 4, 2019

Participant flow

Participant flow — Overall Study
MilestoneINTP5 Biosimilar ProductUS Neulasta Reference Product
Started100100
Completed8993
Not completed117
Withdrew: Withdrawal by subject74
Withdrew: Protocol violation10
Withdrew: Medical grounds33

Outcome measures

PrimaryImmunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.

Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data. Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant. Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.

Time frame:
Samples (8 mL each) were withdrawn at screening, at pre-dose and at 336 (D-15, Week 2), 504 (D-22, Week 3, within 60 minutes before 2nd dose), 840 (D-36, Week 5), 1176 (D-50, Week 7), 1680 (D-71, Week 10) and 2016 (D-85, Week 12) hours after first dose.
Reported as:
Count of participants · Participants
Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.
ParticipantsINTP5 Biosimilar ProductUS Neulasta Reference Product
Positive for Anti-Drug-Antibody109
Positive in Neutralizing Anti-Drug-Antibody00
No Anit-Drug Antibody Confirmed Positive Results8491
SecondaryPK Endpoints: Pegfilgrastim C[Max]

Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration. Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · ng/mL
PK Endpoints: Pegfilgrastim C[Max]
ng/mLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim C[Max]483.230 ± 175.1787346.018 ± 150.4879368.569 ± 223.3380371.778 ± 263.4440
SecondaryPK Endpoints: Pegfilgrastim AUC[0-t]

Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · ng.h/mL
PK Endpoints: Pegfilgrastim AUC[0-t]
ng.h/mLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim AUC[0-t]22417.938 ± 9922.264813640.695 ± 6709.275216610.870 ± 11255.129615255.327 ± 11050.7580
SecondaryPK Endpoints: Pegfilgrastim AUC[0-∞]

Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC\[0-infinity\] is the sum of measurable and extrapolated parts.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · ng.h/mL
PK Endpoints: Pegfilgrastim AUC[0-∞]
ng.h/mLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim AUC[0-∞]22436.497 ± 9922.438313637.403 ± 6699.973616630.861 ± 11253.740615280.376 ± 11058.1142
SecondaryPK Endpoints: Pegfilgrastim T[Max]

The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · h
PK Endpoints: Pegfilgrastim T[Max]
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim T[Max]22.405 ± 3.375820.800 ± 5.593622.226 ± 3.529823.111 ± 2.6667
SecondaryPK Endpoints: Pegfilgrastim λz (Lambda-z)

Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · 1/h
PK Endpoints: Pegfilgrastim λz (Lambda-z)
1/hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim λz (Lambda-z)0.021 ± 0.00710.025 ± 0.01420.022 ± 0.00580.019 ± 0.0074
SecondaryPK Endpoints: Pegfilgrastim R^2 Adjusted

Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R\^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · Coefficient of Determination
PK Endpoints: Pegfilgrastim R^2 Adjusted
Coefficient of DeterminationINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim R^2 Adjusted0.968 ± 0.03790.876 ± 0.1330.974 ± 0.02450.879 ± 0.2339
SecondaryPK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]

The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\[0-t\])/AUC\[0-infinity\]\] x 100.

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · percentage of AUC
PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]
percentage of AUCINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]0.115 ± 0.11060.644 ± 1.44280.230 ± 0.26720.266 ± 0.2664
SecondaryPK Endpoints: Pegfilgrastim t[1/2]

The terminal half-life calculated using the formula 0.693/(lambda-z)

Time frame:
Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
Reported as:
Mean · h
PK Endpoints: Pegfilgrastim t[1/2]
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
PK Endpoints: Pegfilgrastim t[1/2]36.721 ± 11.005236.612 ± 19.621534.172 ± 8.866940.616 ± 14.6054
SecondaryPD Endpoints for Baseline Non-adjusted ANC: E[Max]

Maximum measured absolute neutrophil count (ANC).

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · x10^3cells/uL
PD Endpoints for Baseline Non-adjusted ANC: E[Max]
x10^3cells/uLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE40.72 ± 10.86244.63 ± 11.07738.34 ± 9.92540.62 ± 8.963
ADA-POSITIVE42.89 ± 10.51246.53 ± 9.09338.38 ± 8.21144.96 ± 16.409
SecondaryPD Endpoints for Baseline Non-adjusted ANC: T[Max]

Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · h
PD Endpoints for Baseline Non-adjusted ANC: T[Max]
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE64.710 ± 11.107659.587 ± 14.917063.182 ± 15.876364.637 ± 20.5772
ADA-POSITIVE72.003 ± 0.007267.453 ± 15.709164.002 ± 12.001461.461 ± 29.9401
SecondaryPD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]

Time to reach the maximum measured absolute neutrophil count (ANC)

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · h*ng/mL
PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]
h*ng/mLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE7107.14 ± 1481.9717929.25 ± 1561.2466718.70 ± 1361.9577359.09 ± 1455.570
ADA-POSITIVE7286.53 ± 1744.7378539.99 ± 1522.9356846.77 ± 763.6757761.65 ± 1658.478
SecondaryPD Endpoints for Baseline Adjusted ANC: E[Max]

Maximum measured absolute neutrophil count (ANC).

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · x10^3cells/uL
PD Endpoints for Baseline Adjusted ANC: E[Max]
x10^3cells/uLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE36.50 ± 10.45840.80 ± 11.03833.35 ± 9.18936.56 ± 8.755
ADA-POSITIVE38.37 ± 9.54842.50 ± 10.06134.18 ± 8.50340.76 ± 17.170
SecondaryPD Endpoints for Baseline Adjusted ANC: AUEC[0-t]

Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · x10^3cells*h/uL
PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]
x10^3cells*h/uLINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE4920.26 ± 1339.6745992.49 ± 1555.0624389.55 ± 1140.6555441.01 ± 1478.241
ADA-POSITIVE4967.86 ± 1229.7926539.58 ± 2202.4734578.32 ± 1200.1255676.92 ± 1991.456
SecondaryPD Endpoints for Baseline Adjusted ANC: T[Max]

Time to reach the maximum measured absolute neutrophil count (ANC)

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · h
PD Endpoints for Baseline Adjusted ANC: T[Max]
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE64.617 ± 11.148259.735 ± 14.954665.553 ± 15.888765.043 ± 20.6610
ADA-POSITIVE72.003 ± 0.007267.453 ± 15.709164.002 ± 12.001461.461 ± 29.9401
SecondaryPD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)

First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · h
PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE0.01 ± 0.0070.01 ± 0.0060.01 ± 0.0060.01 ± 0.006
ADA-POSITIVE0.01 ± 0.0060.01 ± 0.0030.01 ± 0.0040.01 ± 0.005
SecondaryPD Endpoints for Baseline Adjusted ANC: t[1/2]

The terminal half-life will be calculated as 0.693/(lambda-z)

Time frame:
Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
Reported as:
Mean · h
PD Endpoints for Baseline Adjusted ANC: t[1/2]
hINTP5 Dose 1INTP5 Dose 2US Neulasta Dose 1US Neulasta Dose 2
ADA-NEGATIVE62.25 ± 28.84764.13 ± 26.78577.23 ± 86.23976.02 ± 59.888
ADA-POSITIVE67.03 ± 41.29669.72 ± 25.44781.74 ± 29.98167.02 ± 22.706

Adverse events

Collected over 99 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INTP5 Biosimilar Product0/100 (0%)0/100 (0%)32/100 (32%)
US Neulasta Reference Product1/100 (1%)1/100 (1%)37/100 (37%)
Most frequent serious events
Most frequent serious events
EventINTP5 Biosimilar ProductUS Neulasta Reference Product
deathGeneral disorders0/1001/100
Most frequent other events
Showing 10 of 27
Most frequent other events
EventINTP5 Biosimilar ProductUS Neulasta Reference Product
Musculoskeletal painMusculoskeletal and connective tissue disorders16/10015/100
HeadacheNervous system disorders6/10013/100
VomitingGastrointestinal disorders5/1005/100
Injection site painGeneral disorders5/1004/100
InjuryInjury, poisoning and procedural complications0/1003/100
Red blood cells urine positiveInvestigations3/1000/100
DiarrhoeaGastrointestinal disorders0/1002/100
PyrexiaGeneral disorders2/1000/100
EosinophiliaBlood and lymphatic system disorders1/1000/100
Abdominal painGastrointestinal disorders1/1000/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
Mean31.5 ± 6.8234.3 ± 6.0532.9 ± 6.58
Sex: Female, Male
Sex: Female, Male(Participants)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
Female404080
Male6060120
Race (NIH/OMB)
Race (NIH/OMB)(Participants)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
American Indian or Alaska Native000
Asian100100200
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
India100100200
Height
Height(cm)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
Mean160.2 ± 8.48160.1 ± 8.68160.2 ± 8.56
Weight
Weight(kg)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
Mean61.3 ± 8.3162.6 ± 7.4961.9 ± 7.92
BMI
BMI(kg/m^2)INTP5 Biosimilar ProductUS Neulasta Reference ProductTotal
Mean23.95 ± 3.06924.51 ± 3.26624.23 ± 3.173
08

Study locations

1 site
  • Lambda Therapeutic Research Ltd.
    Ahmedabad, Gota 382481, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jun 2018, 3 months.

Results were first posted in Oct 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 10, 2019
StartActual
Feb 26, 2018
Primary completionActual
Jun 5, 2018
CompletionActual
Jun 5, 2018
Results first posted
Oct 4, 2019
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04015232
Lead sponsor
Intas Pharmaceuticals, Ltd.
Collaborators
Lambda Therapeutic Research Ltd.
Responsible party
Sponsor
First posted
Jul 10, 2019
Start date
Feb 26, 2018
Primary completion
Jun 5, 2018
Completion
Jun 5, 2018
Results posted
Oct 4, 2019
Last update
Oct 4, 2019

Study contacts

Adarsh K Garg, M.B.B.S
principal investigator · Lambda Therapeutic Research Ltd.
Vinu Jose, M.D.
study director · Intas Pharmaceuticals, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion